Medeon Biodesign Cash Flow-to-Debt Ratio
Medeon Biodesign cash flow-to-debt ratio. Medeon Biodesign (6499) has a Cash Flow-to-Debt Ratio of -0.33x as of June 2026, meaning its operating cash flow of NT$-93.35 Million could theoretically repay 0% of its total liabilities (NT$282.14 Million) in one year. Check Medeon Biodesign cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Medeon Biodesign (2017–2025)
Cash flow-to-debt ratio of Medeon Biodesign from 2017 to 2025. Historical debt coverage capacity for Medeon Biodesign across 9 annual periods. Check 6499 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Medeon Biodesign Cash Flow-to-Debt Ratio by Year (2017–2025)
Medeon Biodesign cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Medeon Biodesign. For the full cash flow conversion analysis, see Medeon Biodesign (6499) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.59x | NT$-629.14 Million | NT$243.03 Million | ▼ -6.3% |
| 2024 | -2.44x | NT$-832.66 Million | NT$341.84 Million | ▼ -21.2% |
| 2023 | -2.01x | NT$-755.08 Million | NT$375.65 Million | ▼ -64.0% |
| 2022 | -1.23x | NT$-461.34 Million | NT$376.48 Million | ▲ +26.5% |
| 2021 | -1.67x | NT$-293.38 Million | NT$176.00 Million | ▼ -634.8% |
| 2020 | -0.23x | NT$-151.27 Million | NT$666.83 Million | ▲ +74.9% |
| 2019 | -0.90x | NT$-241.99 Million | NT$268.18 Million | ▼ -141.7% |
| 2018 | 2.16x | NT$322.05 Million | NT$148.89 Million | ▲ +173.4% |
| 2017 | -2.95x | NT$-310.76 Million | NT$105.41 Million | — |